Research programme: cancer therapeutics - Endocyte

Drug Profile

Research programme: cancer therapeutics - Endocyte

Alternative Names: CB-3717; EC 0531; EC 0651; EC 1812; EC 1868; EC 1977; EC 2629; EC-1744; EC1788; GARFTase inhibitors - Endocyte; PNU-159682

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Endocyte
  • Developer Endocyte; Purdue University
  • Class CAR-T cell therapies; Cell therapies; Depsipeptides; Doxorubicins; Drug conjugates; Folic-acids; Oligopeptides; Small molecules; Taxanes
  • Mechanism of Action Folate receptor 1 antagonists; Glutamate carboxypeptidase II inhibitors; Immunostimulants; Phosphoribosylglycinamide formyltransferase inhibitors; Tubulin polymerisation inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Haematological malignancies
  • Research Cancer
  • No development reported Prostate cancer; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Prostate-cancer in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA
  • 08 Aug 2017 Endocyte files an IND application with the US FDA for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top